Grifols S.A. (GRF) - Total Liabilities
Based on the latest financial reports, Grifols S.A. (GRF) has total liabilities worth €12.17 Billion EUR (≈ $14.23 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Grifols S.A. - Total Liabilities Trend (2005–2024)
This chart illustrates how Grifols S.A.'s total liabilities have evolved over time, based on quarterly financial data. See how liquid is Grifols S.A.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Grifols S.A. Competitors by Total Liabilities
The table below lists competitors of Grifols S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Air Canada
TO:AC
|
Canada | CA$30.37 Billion |
|
Cencosud Shopping SA
SN:CENCOMALLS
|
Chile | CL$1.51 Trillion |
|
Shandong Intco Medical Products Co Ltd
SHE:300677
|
China | CN¥21.50 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥47.87 Billion |
|
AAR Corp
NYSE:AIR
|
USA | $1.69 Billion |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
China | CN¥7.59 Billion |
|
Hangzhou Cable
SHG:603618
|
China | CN¥8.06 Billion |
|
Grifols S.A
F:G0FB
|
Germany | €12.11 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Grifols S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Grifols S.A. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grifols S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grifols S.A. (2005–2024)
The table below shows the annual total liabilities of Grifols S.A. from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €12.80 Billion ≈ $14.96 Billion |
-4.98% |
| 2023-12-31 | €13.47 Billion ≈ $15.75 Billion |
+3.00% |
| 2022-12-31 | €13.08 Billion ≈ $15.29 Billion |
+17.95% |
| 2021-12-31 | €11.09 Billion ≈ $12.96 Billion |
+29.60% |
| 2020-12-31 | €8.55 Billion ≈ $10.00 Billion |
-1.63% |
| 2019-12-31 | €8.70 Billion ≈ $10.17 Billion |
+11.78% |
| 2018-12-31 | €7.78 Billion ≈ $9.10 Billion |
+6.78% |
| 2017-12-31 | €7.29 Billion ≈ $8.52 Billion |
+13.82% |
| 2016-12-31 | €6.40 Billion ≈ $7.48 Billion |
+1.61% |
| 2015-12-31 | €6.30 Billion ≈ $7.37 Billion |
+8.87% |
| 2014-12-31 | €5.79 Billion ≈ $6.77 Billion |
+54.98% |
| 2013-12-31 | €3.73 Billion ≈ $4.37 Billion |
-0.34% |
| 2012-12-31 | €3.75 Billion ≈ $4.38 Billion |
-9.56% |
| 2011-12-31 | €4.14 Billion ≈ $4.84 Billion |
+250.61% |
| 2010-12-31 | €1.18 Billion ≈ $1.38 Billion |
+9.54% |
| 2009-12-31 | €1.08 Billion ≈ $1.26 Billion |
+54.32% |
| 2008-12-31 | €698.96 Million ≈ $817.16 Million |
+25.85% |
| 2007-12-31 | €555.40 Million ≈ $649.32 Million |
+1.85% |
| 2006-12-31 | €545.32 Million ≈ $637.54 Million |
-28.78% |
| 2005-12-31 | €765.74 Million ≈ $895.23 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more